User:Mr. Ibrahem/Selpercatinib

Selpercatinib, sold under the brand name Retevmo, is a medication used to treat certain types of non-small cell lung cancer and thyroid cancer. It is used in cases that are either RET fusion positive or have a RET gene mutation. It is used after other treatments have failed. It is taken by mouth.

Common side effects include liver problems, high blood sugar, dry mouth, diarrhea, kidney problems, tiredness, swelling, low platelets, and rash. Other side effects may include high blood pressure, QT prolongation, bleeding, allergic reactions, and tumor lysis syndrome. Use in pregnancy may harm the baby. It is a kinase inhibitor, which blocks RET.

Selpercatinib was approved for medical use in the United States in 2020 and Europe in 2021. In the United States it costs about 258,000 USD per year as of 2021. It has also bee approved in the United Kingdom.